New pill targets brain inflammation in Parkinson's – first human tests begin
NCT ID NCT06997484
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-stage trial tests an experimental oral drug called HL-400 in 86 healthy volunteers. The drug aims to block a protein (NLRP3) linked to inflammation, which may play a role in Parkinson's disease. The study focuses on safety, tolerability, and how the drug moves through the body, not yet on treating Parkinson's symptoms.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
HL-400 (an oral NLRP3 inhibitor)
What this could lead to
If successful, this could pave the way for a new treatment that slows Parkinson's disease by targeting inflammation in the brain.
What could go wrong
This is a very early Phase 1 trial in healthy people, not Parkinson's patients. It only tests safety and dosing, not whether the drug works for the disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PARKINSON DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Pharmaron CPC, Inc.
RECRUITINGBaltimore, Maryland, 21201, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••